[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607729":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":56,"collaborators":25,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":25,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":25,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":25,"overallStatus":37,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Kafrelsheikh University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group S","EXPERIMENTAL","Patients will be treated with conventional anti-heart failure therapy plus sacubitril\u002Fvalsartan (oral administration of an initial dose of 24\u002F26 mg twice daily, gradually increasing to 97\u002F103 mg, depending on follow-up blood pressure) \\[Entresto, 100 mg (sacubitril 49 mg\u002Fvalsartan 51 mg)\\].",[13],"Drug: Sacubitril\u002FValsartan",{"label":15,"type":16,"description":17,"interventionNames":18},"Group C","ACTIVE_COMPARATOR","Patients will be treated only with conventional anti-heart failure therapy as a control group.",[19],"Drug: Conventional anti-heart failure therapy",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Sacubitril\u002FValsartan",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Conventional anti-heart failure therapy",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Mohammed A Hammad, MD","CONTACT","00201015928694","drhammad879@gmail.com",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Kafr ash Shaykh","Kafrelsheikh","33516","Egypt","EG",{"type":44,"coordinates":45},"Point",[46,47],30.93991,31.11174,{"lat":47,"lon":46},[50,51,54],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"name":52,"role":53,"phone":25,"phoneExt":25,"email":25},"Wael A Hassib, MD","PRINCIPAL_INVESTIGATOR",{"name":55,"role":53,"phone":25,"phoneExt":25,"email":25},"Mohamed K Salama, MD",{"type":53,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Mohammed Ali Mohammed Hammad","Lecturer of Cardiology, Faculty of Medicine, Kafr Elsheikh University, Kafr Elsheikh, Egypt.","100607729","sacubitrilvalsartan-in-patients-with-prosthetic-heart-valves-with-heart-failure-and-reduced-ejection-fraction-100607729",false,"NCT07192341","Sacubitril\u002FValsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction","Effect of Sacubitril\u002FValsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* Both sexes.\n* Patients with a history of prosthetic heart valves.\n* Patients diagnosed with heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40% with New York Heart Association (NYHA) functional class II-IV.\n\nExclusion Criteria:\n\n* Hemodynamic instability.\n* Use of a circulatory auxiliary circulation device.\n* Severe hepatic \\[alanine aminotransferase (ALT) \\>120 U\u002FL\\] and renal insufficiency \\[estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\\].\n* Blood pressure \\\u003C100\u002F60 mmHg.\n* Serum potassium \\>5.3 mmol\u002FL.\n* Severe pulmonary hypertension.\n* Malignant arrhythmia.\n* Malignant tumor.\n* Known history of hereditary or primary angioedema.\n* Serious adverse drug reactions or serious complications over the course of treatment.","ALL","18 Years",{"count":69,"type":70},220,"ESTIMATED","INTERVENTIONAL",[73],"NA","This study aims to evaluate the effect of sacubitril\u002Fvalsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).",[23,76,77,78],"Prosthetic Heart Valve","Heart Failure","Reduced Ejection Fraction","2025-09-27",{"date":81,"type":82},"2025-09-30","ACTUAL",{"date":79,"type":82},{"date":85,"type":70},"2026-02-01",{"name":5,"class":6},1]